CBIO

Catalyst BiosciencesNasdaqCM:CBIO Stock Report

Market Cap

US$162.5m

7D

2.9%

1Y

10.6%

Updated

20 Sep, 2021

Data

Company Financials +
CBIO fundamental analysis
Snowflake Score
Valuation3/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

CBIO Overview

Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation.

Share Price & News

How has Catalyst Biosciences's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CBIO is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: CBIO's weekly volatility (7%) has been stable over the past year.


Market Performance


7 Day Return

2.9%

CBIO

-0.7%

US Biotechs

-2.5%

US Market


1 Year Return

10.6%

CBIO

25.9%

US Biotechs

33.0%

US Market

Return vs Industry: CBIO underperformed the US Biotechs industry which returned 25.9% over the past year.

Return vs Market: CBIO underperformed the US Market which returned 33% over the past year.


Shareholder returns

CBIOIndustryMarket
7 Day2.9%-0.7%-2.5%
30 Day24.7%1.1%-0.9%
90 Day15.8%3.9%0.8%
1 Year10.6%10.6%27.5%25.9%35.0%33.0%
3 Year-52.1%-52.1%16.3%11.0%57.6%47.9%
5 Year-73.9%-73.9%47.4%36.0%120.8%96.7%

Long-Term Price Volatility Vs. Market

How volatile is Catalyst Biosciences's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Catalyst Biosciences Fundamentals Summary

How do Catalyst Biosciences's earnings and revenue compare to its market cap?
CBIO fundamental statistics
Market CapUS$162.47m
Earnings (TTM)-US$77.31m
Revenue (TTM)US$5.52m

27.8x

P/S Ratio

-2.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CBIO income statement (TTM)
RevenueUS$5.52m
Cost of RevenueUS$63.97m
Gross Profit-US$58.44m
ExpensesUS$18.86m
Earnings-US$77.31m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-2.97
Gross Margin-1,058.21%
Net Profit Margin-1,399.71%
Debt/Equity Ratio0%

How did CBIO perform over the long term?

See historical performance and comparison

Valuation

Is Catalyst Biosciences undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: CBIO ($4.9) is trading below our estimate of fair value ($72.8)

Significantly Below Fair Value: CBIO is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: CBIO is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: CBIO is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CBIO's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CBIO is good value based on its PB Ratio (1.8x) compared to the US Biotechs industry average (3.1x).


Future Growth

How is Catalyst Biosciences forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

38.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CBIO is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CBIO is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CBIO is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CBIO's revenue (71.2% per year) is forecast to grow faster than the US market (9.8% per year).

High Growth Revenue: CBIO's revenue (71.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if CBIO's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Catalyst Biosciences performed over the past 5 years?

-29.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CBIO is currently unprofitable.

Growing Profit Margin: CBIO is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: CBIO is unprofitable, and losses have increased over the past 5 years at a rate of 29.7% per year.

Accelerating Growth: Unable to compare CBIO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CBIO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).


Return on Equity

High ROE: CBIO has a negative Return on Equity (-90.77%), as it is currently unprofitable.


Financial Health

How is Catalyst Biosciences's financial position?


Financial Position Analysis

Short Term Liabilities: CBIO's short term assets ($96.8M) exceed its short term liabilities ($15.6M).

Long Term Liabilities: CBIO's short term assets ($96.8M) exceed its long term liabilities ($1.1M).


Debt to Equity History and Analysis

Debt Level: CBIO is debt free.

Reducing Debt: CBIO has no debt compared to 5 years ago when its debt to equity ratio was 129.4%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CBIO has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: CBIO has sufficient cash runway for 1.4 years if free cash flow continues to reduce at historical rates of 26.4% each year.


Dividend

What is Catalyst Biosciences's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CBIO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CBIO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CBIO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CBIO's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CBIO's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.0yrs

Average management tenure


CEO

Nassim Usman (61 yo)

6.08yrs

Tenure

US$1,409,622

Compensation

Dr. Nassim Usman, Ph.D. serves as a Venture Partner at Morgenthaler Ventures. Dr. Usman is a part of the life sciences team. He joined Morgenthaler as an Entrepreneur-in-Residence in 2005 and has also serv...


CEO Compensation Analysis

Compensation vs Market: Nassim's total compensation ($USD1.41M) is about average for companies of similar size in the US market ($USD1.10M).

Compensation vs Earnings: Nassim's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: CBIO's management team is not considered experienced ( 1 years average tenure), which suggests a new team.


Board Members

Experienced Board: CBIO's board of directors are considered experienced (5.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: CBIO insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 42.2%.


Top Shareholders

Company Information

Catalyst Biosciences, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Catalyst Biosciences, Inc.
  • Ticker: CBIO
  • Exchange: NasdaqCM
  • Founded: 2002
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$162.474m
  • Shares outstanding: 31.37m
  • Website: https://www.catalystbiosciences.com

Number of Employees


Location

  • Catalyst Biosciences, Inc.
  • 611 Gateway Boulevard
  • Suite 710
  • South San Francisco
  • California
  • 94080
  • United States

Listings


Biography

Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation. The company engineer proteas...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/20 22:34
End of Day Share Price2021/09/20 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.